• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Partial Seizure - Pipeline Review, H2 2012 Product Image

Partial Seizure - Pipeline Review, H2 2012

  • Published: October 2012
  • 78 pages
  • Global Markets Direct

Partial Seizure – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Partial Seizure - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Partial Seizure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Partial Seizure. Partial Seizure - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Partial Seizure.
- A review of the Partial Seizure products under development by companies and universities/research institutes based READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Partial Seizure Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Partial Seizure 8
Partial Seizure Therapeutics under Development by Companies 10
Partial Seizure Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Partial Seizure Therapeutics – Products under Development by Companies 17
Partial Seizure Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Partial Seizure Therapeutics Development 19
Novartis AG 19
Eisai Co., Ltd. 20
UCB Group 21
Catalyst Pharmaceutical Partners, Inc. 22
Upsher-Smith Laboratories, Inc. 23
Ache Laboratorios Farmaceuticos S/A 24
Marinus Pharmaceuticals, Inc. 25
Sihuan Pharmaceutical Holdings Group Ltd. 26
Partial Seizure – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
brivaracetam - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
perampanel - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
perampanel - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
zonisamide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
levetiracetam - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
YKP-3089 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CPP-115 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BGG-492 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
topiramate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ganaxolone - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Eicosapentaenoic Acid + Docosahexaenoic Acid - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
levetiracetam - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
levetiracetam - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Partial Seizure Therapeutics – Drug Profile Updates 55
Partial Seizure Therapeutics – Discontinued Products 67
Partial Seizure Therapeutics - Dormant Products 68
Partial Seizure – Product Development Milestones 69
Featured News & Press Releases 69
Oct 04, 2012: Eisai Presents Phase III Data Supporting Europe's Newest Partial Epilepsy Treatment Fycompa At European Congress On Epileptology 69
Sep 24, 2012: UCB Sponsors Data Presentations On Epilepsy, Including New Data On Brivaracetam At 10th European Congress On Epileptology 70
Sep 24, 2012: UCB Sponsors Data Presentations On Epilepsy, Including New Data On Vimpat At 10th European Congress On Epileptology 71
Sep 24, 2012: UCB Sponsors Data Presentations On Epilepsy, Including New Data On Keppra At 10th European Congress On Epileptology 72
Sep 13, 2012: Eisai Launches Fycompa For Treatment Of Epilepsy 72
Aug 22, 2012: Eisai Announces Publication Of Final Pivotal Phase III Fycompa Study Results In Epilepsia 73
Jul 27, 2012: European Commission Approves Eisai's AMPA Receptor Antagonist Fycompa 74
Jul 25, 2012: Eisai Announces Publication Of Phase III Results Of Perampanel In Neurology 75
Jul 23, 2012: Pfizer Reports Top-Line Results Of Study Of Lyrica’s Effect On Male Reproduction Conducted As Post-Approval Commitment Required By FDA 75
Jul 03, 2012: Eisai Receives EMA Approval To Market Zonegran Monotherapy For Treatment Of Epilepsy 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78

List of Tables
Number of Products Under Development for Partial Seizure, H2 2012 8
Products under Development for Partial Seizure – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Novartis AG, H2 2012 19
Eisai Co., Ltd., H2 2012 20
UCB Group, H2 2012 21
Catalyst Pharmaceutical Partners, Inc., H2 2012 22
Upsher-Smith Laboratories, Inc., H2 2012 23
Ache Laboratorios Farmaceuticos S/A, H2 2012 24
Marinus Pharmaceuticals, Inc., H2 2012 25
Sihuan Pharmaceutical Holdings Group Ltd., H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Partial Seizure Therapeutics – Drug Profile Updates 55
Partial Seizure Therapeutics – Discontinued Products 67
Partial Seizure Therapeutics – Dormant Products 68

List of Figures
Number of Products under Development for Partial Seizure, H2 2012 8
Products under Development for Partial Seizure – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos